Moreau, Philippe <br/><br/>
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.  [electronic resource] 

 -  Haematologica  May 2015 
 - e207-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2014.118182  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Cutaneous<br/>Administration, Intravenous<br/>Antineoplastic Agents--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Humans<br/>Multiple Myeloma--complications<br/>Neoplasm Recurrence, Local<br/>Pyrazines--administration & dosage<br/>Renal Insufficiency--etiology<br/>Treatment Outcome